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Abstract Inrecent years, manyauthorshavedescribed severalcasesrevealinganassociationbetweenhyperthyroid-
ism and pulmonary hypertension (PH). This observational study was designed to evaluate the incidence of PH in hy-
perthyroidism and was set in a department of internal medicine and pulmonary diseases with an out-patients
departmentof endocrinology.Thirty-fourpatients, 25 women andninemen, with amean age of 38+15 SD years partici-
pated. Twenty had Graves’disease and 14 had a nodular goitre. The patients were divided into two equally matched
groups: thosewith a recentlydiagnosedhyperthyroidism, takingno drugs (group1; n=17) and those in a euthyroid state
takingmethimazole (group 2; n=17).
Transthoracic Dopplerechocardiographywasperformedand systolicpulmonaryarterypressurementsof (PAPs) was
determined by the tricuspid regurgitationmethod using the Bernoulli equation.Measurements of triiodothyronine, tet-
raiodothyronine, free thyroxine (Ft4), thyroid-stimulating hormone (TSH) and antithyroglobulin and antimicrosomal
antibodieswere alsotaken.We found amild PHin sevenpatients ofgroup1andinnone ofgroup 2.Themean+SDsystolic
pulmonaryarterypressurewas 28?88+6?41ingroup1and 22?53+1?84 ingroup 2 (Po0?0001).Acorrelationwas found
between theTSH value and PAPs (r=0?82;Po0?001) and Ft4 and PAPs (r=0?85;Po0?001) in group1.These findings
indicate the presence of a frequent association between PH and hyperthyroidism.We suggest that hyperthyroidism be
included inthe differential diagnosis of PH.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1260, available online at http://www.idealibrary.comon
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hormones.INTRODUCTION
Primary pulmonary hypertension (systolic pulmonary
artery pressure430mmHg at rest and at sea level) is a
rare, progressive, and often fatal disease of unknown
cause. The disease is most common in women (ratio
1?7:1) and the mean age at the time of diagnosis is the
mid 30s (1).However, the incidence of pulmonary hyper-
tension (PH) is increased in various clinical settings such
as autoimmune diseases (2,3), liver cirrhosis with portal
hypertension (4), HIV infection (5), use of anorectic
drugs or oral contraceptives (6^9), sleep apnoea syn-
drome (10^14) and endocrinopathies (hypothyroidism
and hyperthyroidism) (15^17).
Cardiovascular manifestations are multiform and fre-
quent in hyperthyroidism. These include sinus tachycar-
dia and atrial dysrhythmias, decreased exercise
tolerance, cardiomegaly, increased cardiac output and,
in some cases, congestive heart failure (18^21). In recent
years, many authors have suggested an association be-Presented in part at the A.C.C.P. Annual Congress,Chicago,1999.
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(15,16,22,23).
We think that clinical conditions associated with PH
may help to ¢nd a common underlying aetiologic me-
chanism as well as to elucidate its pathogenesis.
Our study was designed to measure systolic pulmon-
arypressure and to assess the incidence of PHinpatients
with hyperthyroidsm.To our knowledge, these data are
not available in English language literature.
MATERIALSANDMETHODS
We studied 34 patients, 25 women and ninemen, whose
mean(+SD) age was 38+15 years. Twenty of these
patients had Graves’ disease and 14 had a nodular goitre
(Tables 1 and 2). All patients were ambulatory and were
recruited from the Endocrinology out-patients depart-
ment in a consecutive order (from May 1997 to April
1999). The diagnosis of hyperthyroidism was made by
clinical examination and con¢rmed by measuring free
triiodothyronine (FT3), free thyroxine (FT4) and thyr-
oid-stimulating hormone (TSH). We excluded smoking
subjects and patients taking anorectic, contraceptive,
chemotherapeutic and vasoactive drugs (b,calcium
TABLE 1. Patients Characteristics andresults
Group1 (n=17) Group 2 (n=17) P value
Male/female 4/13 5/12 n.s.
Age (yrs) 38?53+9?58 37+16 n.s.
N.G./G.D. 7/10 6/11 n.s.
PAPsmmHg 28?88+6?41 22?53+1?84 Po0?0001
C.O.L min1 4?96+0?64 4?66+0?76 n.s.
H.R. beatsmin1 83?80+8?57 81?0+7?51 n.s.
T.S.H. value* 0?06+0?04 2?78+1?22 Po0?001
FT4 value** 24?86+3?77 16?49+5?46 Po0?001
Antithyroglobulin Ab# 407?30+56?76 347?17+90?16 P=0?096
BMIkgm2 22?8+2?4 23?1+2?9 n.s.
pH 7?38+0?021 7?39+0?023 n.s.
PaO2 mmHg 86?8+7?9 87?3+8?5 n.s.
FEV1?0% 92?3+11?3 94?9+10?6 n.s.
FVC % 95?0+12?1 95?7+11? 8 n.s.
Systolic bloodpressure 136?86+4?81 129?0+15?93 P=0?060
N.G.=nodular goitre; G.D.=graves, disease; PAPs=systolic pulmonary artery pressure; C.O.=cardiac output; H.R.=heart
rate; Ab=antibodies.
*reference range=0?1^4?0 mU1; ** reference range=8?5^19 pmol L1 # reference value 0^350 IE ml1; BMI=bodymass
index.
FEV 1?0=one second forced expiratory volume in percentage of predicted volume; FVC=Forced vital capacity. All values
expressed asmean+SD. n.s.=not signi¢cant.
TABLE 2. Baseline characteristics of group1
Patient Age (yrs) Disease PAPs C.O. lmin FT4 A.N.A. Anti-thyr.Ab T.S.H. Syst.BP Diast BP
1 53 G.D. 37 4?31 28 negative 351 0?05 155+5 78?33+2?89
2 25 N.G. 37 4?75 27 negative absent 0?02 116+7?64 68?33+2?89
3 28 G.D. 37 5?31 29?5 pos.1:80 401 0?04 131+2?89 71?67+2?89
4 50 G.D. 40 5?9 30 negative 398 0?02 120+5 71?67+7?64
5 49 G.D. 27 5?50 26?1 negative 460 0?09 105+57 1?67+2?89
6 38 N.G. 21 5?05 23 negative absent 0?10 141+2?89 70+0
7 27 N.G. 25 4?81 22 pos.1:160 absent 0?08 140+5 73?33+5?77
8 45 G.D. 29 5?67 27?8 negative 371 0?04 140+0 71?67+2?89
9 41 G.D. 30 5?7 27?8 negative 491 0?02 140+10 81?67+2?89
10 35 N.G. 24 4?05 25 negative absent 0?07 150+5 78?33+2?89
11 30 G.D. 22 4?00 21?5 negative 501 0?08 138+2?89 63?33+2?89
12 32 N.G. 25 4?15 22 negative absent 0?05 130+5 70+0
13 36 N.G. 30 4?9 26?9 negative absent 0?04 155+5 85+5
14 26 G.D. 35 4?40 28?5 negative 360 0?02 131+7?64 73?33+5?77
15 51 N.G. 24 5?55 20 pos.1:80 absent 0?09 150+5 71?67+2?89
16 48 G.D. 21 5?71 19?1 negative 350 0?08 141+2?89 80+0
17 41 G.D. 25 4?6 18?5 negative 390 0?09 140+5 78?33+2?89
GD=Graves’disease;NG=nodular goitre;PAPs=Systolic pulmonary artery pressure (mmHg); Syst.BP=systolic blood pres-
sure; Diast. BP=diastolic blood pressure; C.O.=cardiac output; FT4=free T4 (pmol l1); anti-nuclear antibodies; Anti-Thyr.
Ab=Antithyroglobulin antibodies (IEml1);T.S.H.=thyroid stimulatinghormonemUl1.
216 RESPIRATORYMEDICINEchannel and a- adrenergic blockers). Patients presented
no pulmonary signs or symptoms of connective tissue
disease. All patients showed a normal chest X-ray, £ow-
volume spirometry, arterial blood gases pattern, hepatic
function (normal serum albumin, aspartate aminotrans-ferase, alanine aminotransferase, and gamma-glutamyl
transpeptidase) and had a left ventricular ejection frac-
tiongreater than 60% and a normalDoppler echocardio-
graphy (no evidence of congenital heart disease or
valvular disease). The human immunode¢ciency virus
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sorbent assay, ELISA) was negative in all patients. None
of them had a history of sleep apnoea syndrome, and
we performed an evaluation of oxygen saturation during
sleep (PulseOxymeter Model VX4-Vitalog; Respironics,
Inc; Murrysville, PA,USA).
The arterial systemic blood pressure was measured
using a sphygmomanometer at three di¡erent times:
the day of enrolment, before venesection and before
echocardiography.
Global spirometry was performed using a dry wedge
spirometer (Vitalograph). Lung volumes were deter-
mined using a closed circuit helium dilution technique.
Lung di¡usion capacity was measured by a single-breath
method corrected by alveolar-volume (Transfer Ma-
chine,Mod.C.;Morgan,U.K.), and transthoracicDoppler
echocardiography (Sim 7000 CFM Challenger, Esaote
Biomedica; Florence, Italy) was performed blindly by
the same cardiologist who was unaware of the patient’s
clinical condition.
To exclude the possibility of pulmonary embolism in
subjects whose pulmonary artery pressure at rest was
greater than 30mmHg, a lung perfusion scan with 99m
Tc macroaggregated albumin particles was performed
andwe excluded thepresence of patchy loss and segmen-
tal perfusion defects consistent with vascular obstruc-
tion.
Determinations of triiodothyronine (T3), tetraio-
dothyronine (T4), free thyroxine (FT4), thyroid-stimulat-
ing hormone (TSH), (chemiluminescence immunoassay)
antinuclear antibodies (ANA), antineutrophil cytoplas-
mic antibodies (ANCA), antithyroglobulin and antimi-
crosomal antibodies (enzyme immunoassay),
antiphospholipid antibodies (ELISA) were performed in
all patients. We also did a complete platelet count
because of their key role in the release and uptake of
serotonin, a potent pulmonary vasoconstrictor (24)
(Sysmex SF-3000. Kobe, Japan; normal value: 130?000^
400?000mm3). Systolic pulmonary artery pressure
(PAPs) was determined in resting subjects at sea level
by the tricuspid regurgitation method using a modi¢ca-
tion of the Bernoulli equation (DP= 4V2, where P is the
systolic transtricuspid gradient and V represents the
maximum velocity recorded in the regurgidant jet): a
noninvasive technique that showed a good correlation
with cardiac catheterization (25^27).
Themethod was executed on the study group and on
17 healthy subjects matched for age and sex used as a
control group (group 3).
To test the extent of interobserver variability, all pa-
tients were analyzed after few minutes by a second in-
vestigator who was blinded to the results obtained by
the ¢rst observer. The variability was low, with a mean
discrepancy of1?0mmHg and a SD of1?9mmHg.
Measurements of cardiac output (CO) were per-
formed at rest from apical two-dimensional echocardio-grams using a modi¢ed Simpson technique and
multiplying systolic stroke volume by heart rate.
Two patients were excluded a woman with possible
rheumatoid arthritis and a man with sleeping apnoea
(snoring and signi¢cant oxygen desaturations during
sleep). The patients were divided into two equally
matched groups for sex, age and kind of disease: those
with a recently diagnosed hyperthyroidism, taking no
drugs (group1, n=17) (Table 2) and others in a euthyroid
state after taking methimazole for 6+3 months (group
2, n=17) (Table1).
After thepurpose of the study was explained to them,
all patients gave their written informed consent. The
study was approved by the local Ethical Committee
which refused to assent to the performance of cardiac
chatheterisation, because all patients were free of pul-
monary and cardiac symptoms.
Statisticalmethod
All data are expressed as mean+SD. Statistical compari-
sons were made using the paired Student’s t-test for
spirometric data. Other variables were evaluated using
the non-parametric Mann^Whitney U test. Correla-
tions between the level of PAPs and TSH, thyroid hor-
mones, anti-thyroglobulins, and anti-microsomal
antibodies were made using Spearman’s rank sum test;
Po0?05 was chosen as the signi¢cance level (GraphPad
Software, Inc, San Diego,CA,USA).
RESULTS
We foundmild PH in seven patients in group1 (35%) and
in none of those in groups 2 and 3 (euthyroid andhealthy
subjects).The mean+SD PAPs was 22?53+1?84 in group
2 and 22?18+1?51 in group 3 vs. 28?88+6?41 in group 1
(Po0?0001) (Table1, Fig.1).
The cardiac output (CO expressed in l min1) was
4?95+0?95 in group 1 vs. 4?66+0?76 in group 2
(P=0?333) (Table1).
There were no di¡erences between groups 1 and 2 in
spirometric parameters (total lung capacity: P=0?300,
and di¡usion lung capacity for carbonmonoxide/alveolar
volume: P=0?561), arterial O2 tension(PaO2 mmHg) and
pH (86?8+7?9mmHg, vs. 87?3+8?5mmHg; 7?38+
0?021, vs. 7?39+0?023) (Table1).
The arterial systolic blood pressurewas136?86+4?81
in group1and129?0+15?93 in group 2 (P=0?060); the ar-
terial diastolic blood pressure was 74?01+3?12 versus
71?69+5?31 (P=0?130).
The platelet countwas 237?53+83?27103 in group1
and 247?65+62?90103 in group 2 (P=0?692).
There was no di¡erence between the two groups
in the level of antimicrosomal and antithyroglobulin
FIG. 1. Pulmonaryarterypressurevalues.Barsindicatemedian
value.
FIG. 3. Correlationbetween FT4 and PAPs values in group1.
FIG. 2. Correlation between TSH (thyroid-stimulating hor-
mone) and PAPs values in group1.
218 RESPIRATORYMEDICINEantibodies (325?70+127?12 vs. 236?50+90?34; P=0?087)
(Table1).
The ANA test was positive at low titre in three pa-
tients of group1and in two patients of group 2 (Table 2).
ANCA and antiphospholipid antibodies were negative in
all subjects.
A correlation was found between theTSH value and
the level of PAPs in group1 (r=0?82; Po0?001) (Fig. 2)
butnot in group 2(r=0?529;P=0?223) andbetween FT4
and the level of PAPs in group1(r=0?85;Po0?001) (Fig. 3)
vs. (r=0?305; P=0?557) group 2. However, there was no
correlation between antithyroid antibodies and PAPs
(P40?05)and between arterial systolic blood pressure
and systolic PAP (r=0?33;P=0?188).
DISCUSSION
An association between thyrotoxicosis and increased
pulmonary artery pressure has been described by sev-
eral authors, each of whomreported the case of a single
patient with elevated PAPs during hyperthyroidism, re-
solving after antithyroid therapy (6,22,23). The largest
series of cases was described by Yanai-Landau et al. (3).
In their group of 40 patientswith PH,were found tohave
30% antithyroglobulin antibodies. The explanation for
this associationwas not clear, but antithyroid antibodies
mightbe amarker for generalized immune activation (3).
Thurnheer and coworkers studied four patients with
thyrotoxicosis(three had elevated thyroid autoantibo-
dies) using Doppler echocardiography and found an ele-
vated PAPs of 40+11mmHg, which decreased to
25+6mmHg after achievement of a euthyroid state (16).
To our knowledge, this is the largest series of cases
and the only study thatexcludes thepresence of antipho-
spholipid antibodies, oxygen desaturation during sleep
and consumption of oral contraceptives.
The current ¢ndings indicate the presence of a fre-
quent associationbetween PHandhyperthyroidism. Pul-
monary hypertension must be attributed to an elevated
pulmonary vascular resistance in the patients studied
here. In fact, these patients show a normal cardiac out-
put and a normalDoppler echocardiography (left ventri-
cular end-diastolic pressure, ejection fraction).Our data
seem to exclude an autoimmune pathogenetic link be-
tween hyperthyroidism and PH as suggested by other
authors (3,15,22,23). In fact, our patients have negative
antiphospholipid antibodies and ANCA tests and there
is no statistical di¡erence between the two groups re-
garding the level of thyroid antibodies. In addition, ANA
are present, at low titre, in three patients of group1and
in two patients of group 2, only one of them has a mild
PAPs (Table 2).
Another possible mechanism may be the direct in£u-
ence of thyroid hormones on pulmonary vasculature.
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tension after normalization of the hyperthyroid state.
Possible explanations include: (i) in£uence of thyroid
hormones which a¡ect growth and maturation of
vascular cells and tissues and have a direct action at the
level of the plasma membrane and endoplasmic reticu-
lum to in£uence the activity of Ca2+ATPase and the
transcellular £ux of substrates and cations (28); (ii) in-
creased metabolism of intrinsic pulmonary vasodilating
substances (prostacyclin, nitric oxide) (15); (iii)decreased
or impaired metabolism of vasoconstrictors (serotonin,
endothelin 1 and thromboxane) (1); (iv) enhanced cate-
cholamine sensitivity causing pulmonary vasoconstric-
tion, reduction of pulmonary artery compliance and
increase in pulmonary vascular resistance (29^31).These
mechanisms may induce a reversible contraction of
smoothmuscle cells.
It is also possible thatmethimazole, which induced im-
munoregulationby a direct inibitorye¡ecton thyrocytes
accompanied by changes in the proportions of T helper-
like and T supressor cells (32), might have some vasoac-
tive properties on pulmonary vasculature.
Andrade demonstrated that administration of methi-
mazole to rats via drinkingwaterprevented the develop-
ment of systemic hypertension that usually accompanies
subtotal nephrectomy and saline (1%NaCl) drinking (33).
Cargas showedhypothyroidism inducedbymethimazole
prevents hypertension caused by NG-nitro-L-arginine
methyl ester (L-NAME), an arginine analogue producing
an acute inibition of NO synthesis (34).
The results of the present study demonstrate a fre-
quent association between hyperthyroidism and transi-
ent pulmonary hypertension, which might be consistent
with an elevated pulmonary vasculare resistance. How-
ever, further studies, with cardiac catheterisation and
valuation of the e¡ects of methimazole on pulmonary
circulation, are needed to verify the exact mechanism
of PH in thyrotoxic patients.
In view of these ¢ndings, we suggest hyperthyroidism
should be included in the di¡erential diagnosis of PH.
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